# Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

> **NCT01068782** · PHASE2 · TERMINATED · sponsor: **Exelixis** · enrollment: 19 (actual)

## Conditions studied

- Astrocytic Tumors

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT01068782
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2011-05
- **Final completion:** 2013-10
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Enrollment in this study was terminated for business development reasons before completing one third of the expected subject population, no formal statistical testing was performed.
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068782, "Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01068782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*